Shrinal Inamdar

Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

Liminal BioSciences Announces Signature of a Share Purchase Agreement for Sale of Remaining Plasma-derived Business with Kedrion

Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

Liminal BioSciences Reports First Quarter 2021 Financial Results

Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business

Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics

LMNL focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics entity.

Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center

Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.

Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.

Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at The ASH Conference

LMNL announced the presentation of two scientific posters highlighting potential activity of intravenous Ryplazim® (plasminogen) on infertility and acute airway obstruction in patients with C-PLGD.

Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference

LMNL is scheduled to present a company overview at The Stifel 2020 Virtual Healthcare Conference on Monday 16th November at 2:40-3:10 PM (EDT)

Liminal BioSciences Reports Third Quarter Financial Results

LMNL today reported its unaudited financial results for the third quarter ended September 30, 2020.

Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call

LMNL will now report its financial results for the third quarter ended September 30th 2020 on Thursday November 12, 2020 after market close.

Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim® (plasminogen) BLA

PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th

Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call

LMNL will report its financial results for the third quarter ended September 30th 2020 on Thursday November 12, 2020 after market close.

Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition

LMNL announced the acceptance of two abstracts related to the Company’s clinical development activities of Ryplazim®